Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.

MLA

Rodenhuis, S., et al. “Efficacy of High-Dose Alkylating Chemotherapy in HER2/Neu-Negative Breast Cancer.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 17, no. 4, Apr. 2006, pp. 588–96. EBSCOhost, https://doi.org/10.1093/annonc/mdl001.

APA

Rodenhuis, S., Bontenbal, M., van Hoesel, Q. G. C. M., Smit, W. M., Nooij, M. A., Voest, E. E., van der Wall, E., Hupperets, P., van Tinteren, H., Peterse, J. L., van de Vijver, M. J., & de Vries, E. G. E. (2006). Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 17(4), 588–596. https://doi.org/10.1093/annonc/mdl001

Chicago

Rodenhuis, S, M Bontenbal, Q G C M van Hoesel, W M Smit, M A Nooij, E E Voest, E van der Wall, et al. 2006. “Efficacy of High-Dose Alkylating Chemotherapy in HER2/Neu-Negative Breast Cancer.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 17 (4): 588–96. doi:10.1093/annonc/mdl001.